A High Grade Diffuse B Cell Lymphoma Patient Presented with Isolated Large Space Occupying Lesion in the Frontal Lobe Mimicking High Grade Glioma or Fungal Granuloma Case Report and Review of Literature by Mazher, Saeed et al.
Pak. J. of Neurol. Surg. – Vol. 20, No. 1, Jan. – Mar., 2016         -8- 
 
 
 
CASE REPORT 
 
 
A High Grade Diffuse B Cell Lymphoma Patient Presented with 
Isolated Large Space Occupying Lesion in the Frontal Lobe 
Mimicking High Grade Glioma or Fungal Granuloma Case 
Report and Review of Literature 
 
SAEED MAZHER, ABDUL ALI KHAN, ABDUL LATIF 
Abdul Khaliq, Shafatullah, Aisha Memon, Muhammed Usman 
Department of Neurosurgery, Baqai University Hospital, Nazimabad 
 
ABSTRACT 
Primary high grade B-cell-type cerebral lymphoma is a rare subtype of primary central nervous system lym-
phoma. We herein report an unusual case of diffuse B-cell lymphoma in a young lady who presented with a large 
intracerebral space occupying lesion without extracranial involvement. The notable aspects of this case include 
the patient was having a short clinical history of symptom onset, rapid neurological deterioration having severe 
midline shift on imaging and a final histopathological diagnosis was consistent with high-grade diffuse B cell 
lymphoma after subtotal surgical resection. Extracranial extension of the disease was unremarkable on PET 
scanning. This case highlights the challenges neurosurgeons face, especially in the emergency setting, when the 
disease manifests in varied presentations. 
Key words:  Rare unusual case, high grade DLBCL, Large Intracerebral Frontal Lobe Lesion, Positron Emission 
Tomographic scanning, Radiotherapy. 
Abbreviations:  DLBCL: Diffuse large B-cell lymphoma. CHOP: Cyclophosphamide, Doxorubicin, Vincristine 
and Prednisone. PCNSL: Primary central nervous system lymphoma. GFAP: Glial Fibrillary Acid Protein. 
IHC: Immunohistochemical. PET: Positron emission tomographic. 
 
INTRODUCTION 
Diffuse large B-cell lymphoma is the most common 
non-Hodgkin lymphoma, making up approximately 
30% to 35% of all cases. Our ability to care for pati-
ents with diffuse large B-cell lymphoma has improved 
dramatically during the past 40 years.
1
 
 In 2007 I had the opportunity to describe my treat-
ment approach for patients with diffuse large B-cell 
lymphoma in an article published in the journal blood.
2
 
 Diffuse large B-cell lymphoma (DLBCL) is the 
most common non-Hodgkin lymphoma. While CHOP 
(Cyclophosphamide, Doxorubicin, Vincristine and 
Prednisone) was the standard combination chemo-
therapy for 25 years, the incorporation of the CD20 
antibody rituximab at the beginning of this century has 
considerably improved the outcome of all patients with 
DLBCL: Depending on the prognostic subgroup, only 
half to one – third of the patients die of their DLBCL 
compared to pre-rituximab era. Treatment is usually 
tailored according to the individual risk profile of a 
Diffuse Large B Cell Lymphoma patient according to 
the International Prognostic Index (IPI).
3
 There are 
several subtypes of Diffuse Large B Cell Lymphoma 
that may affect the prognosis and treatment protocols. 
As DLBCL that only affect the brain is called Primary 
Central Nervous System Lymphoma and treated diffe-
rently that DLBCL that affect areas outside the brain. 
 It is worth to emphasize the significance of other 
cases reported in the literature, such as primary dural 
involvement by diffuse large B-cell lymphoma is 
extremely rare
4
. There is also one report published to 
reveal subdural involvement. Another 77 years old 
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patient presented with an isolated primary central ner-
vous system lymphoma (PCNSL) of the fourth vent-
ricle without extra cranial involvement.
5 
 Our objective is to highlight the significance of 
prompt mandatory surgical intervention to establish 
early tissue diagnosis which can help in further defi-
nitive treatment in terms of adjuncts as chemo radio-
therapy to uplift the patient’s quality of survival with 
consideration of decreased morbidity and mortality. 
 
CASE REPORT 
History and Presentation 
A 28 year old lady Fareeda presented with the symp-
toms of double vision, head ache for about one month. 
Since last week she had been experiencing vomiting 
and walking difficulty, which was so severe that she 
got herself admitted under neurosurgical care through 
the emergency department after getting her Magnetic 
Resonance Imaging done. 
 After admitting under neurosurgical care, prophy-
lactic antiepileptic Levetiracetam started along with 
osmotic diuretic and steroids to decrease the vasogenic 
edema and mass effect associated with the lesion. 
 On neurological examination, markedly thin lean 
lady having right sided partial ptosis and papilla-
edema. She was able to move her all four limbs with 
grade – 4/5 power having both plantars upgoing. She 
was vitally stable and systemic review was normal. 
Rest of the examination was unremarkable. 
 On Magnetic Resonance imaging she was found 
to have a large intracranial lesion measuring approx 
4x5cm in the frontal lobe on right side causing severe 
midline shift. Thorough workup was performed in 
terms of surgical planning. Blood biochemistry includ-
ing clotting profile and urea creatinine and electrolytes 
were performed and found in normal range. In addition 
HIV screening was done which revealed negative 
result. 
 Five packed cells and five fresh frozen plasma cel-
ls were requested with a preoperative plan to perform 
the near total excision. The laboratory workup regard-
ing patient’s Lactate dehydrogenase levels found with-
in normal limits i.e. 275u/l. After subtotal resection, 
histopathology revealed high grade Diffuse Large B-
cell Lymphoma, her PET scan was done which sho-
wed no extra cranial involvement. 
 Soon after surgical intervention patient remained 
in the Intensive care unit for about two days. As the 
duration of surgery was about three to four hours ini-
tially patient was given sedative and paralyzing agents 
to avoid peak episodes of raised intracranial pressures. 
While in the next 24 hours she was well neurologically 
hence her air way was maintained and endotracheal 
tube was removed. Surgical wound care was done on 
regular basis. She showed uneventful recovery and 
stepped down to Neurosurgical department. 
 
Intervention 
Preoperatively subtotal resection was planned. There-
fore right sided transcortical frontal approach was per-
formed. Intra-operatively after identification of grayish 
abnormal brain tissue in the middle and inferior frontal 
lobe initially biopsy was taken followed by subtotal 
resection with caution to avoid an entry inside the ven-
tricular system. 
 Under general anesthesia with specific neuro-pro-
tective protocol, right sided pterional craniotomy was 
performed considering all aseptic measures. After-
wards dura was open in flap fashion having base to-
wards sphenoid sinus after induction of all measures to 
decrease down the intracranial pressure. Cortical incis-
ion was given arachnoid opened with consideration of 
preserving normal vessels. After identification of the 
lesion by the help of biopsy brain needle at the depth 
of 1.5 cm the intra-cerebral lesion was targeted proper 
biopsy was taken and subtotal resection was done 
under operating microscope, with consideration of 
minimal damage to the normal tissue of brain. Most 
importantly complete resection was avoided because 
of the anticipation of unwanted ventricular access. 
Meticulous hemostasis was done. The abnormal brain 
tissue was sent for the histopathology. It was clearly 
reported as high grade B-cell lymphoma with stains 
reveled as CD20 positive and Ki67 approximately 60 to 
70%. 
 Microscopic examination revealed a highly cellu-
lar neoplastic lesion composed of sheets of large size 
atypical lymphoid cells invading into the glial tissue. 
These neoplastic cells had moderate amount of ampho-
philic cytoplasm and markedly pleomorphic, hyper-
chromatic to vesicular nuclei with prominent nucleoli 
and showed brisk mitotic activity. Perivascular lym-
phoid cuffing and areas of necrosis were also seen 
(Figures 1 and 2). 
 The neoplastic population expressed diffuse 
membranous positivity for Pan B (CD20) and negative 
expression for Pan T (CD3) immunohistochemical 
(IHC) stains. Ki67 (Mib1) index was high (approxi-
mately 70%). Glial Fibrillary Acid Protein (GFAP) 
IHC stain only highlighted scattered residual glial 
tissue (Figure 3). 
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 After uneventful recovery patient remained in the 
Intensive care unit for about 48 hrs with special moni-
toring and aggressive supportive therapy in terms of 
sedation and paralysis. After 24 hrs she was weaned 
off from the ventilator support with complete recovery 
of consciousness. Then she was stepped down to Neu-
rosurgery department. She remained well on antibiotic 
and anticonvulsant therapy along with tapering doses 
of osmotic diuretic and steroids. She was discharged to 
oncology department where the further definitive man-
agement was planned after performing the PET / CT 
scans and subsequent staging. It was reported as isola-
ted intensely FDG avid lesion in the brain measuring 
55 mm in AP direction, 45 mm in transverse, 47 mm 
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in craniocaudal direction  and rest of the distant body 
systems uptake were negative. 
 
 
 
Fig. 3: Diffuse sheets of large atypical cells infiltrating into 
glial tissue. Arrow indicates perivascular lymphoid 
cuffing i.e. the tumor cells are concentrated and 
concentrically arranged around a blood vessel. 
(H&E stain, 200 × magnification). 
 
Post Intervention Course 
She remained in the hospital for thirteen days. After 
ten days her alternate stitches were removed wound 
was completely normal without signs of inflammation. 
After further one week on review visit all the stitches 
were removed. She has been improving on radiothe-
rapy on planned review visits. 
 In follow up visits the patient was improving neu-
rologically after initial planned radiotherapy cycles 
recommended by the consultant oncologist. 
 Moreover specific chemotherapy was in the con-
sideration of treating consultant oncologist, provided 
the patient’s general condition is better in terms of pro-
per intake of nutrition. Initially in the tumor board dis-
cussion with oncologist’s bone marrow transplant was 
under discussion which was superseded by PET / CT 
scanning as it is non invasive and effective to finalize 
the definitive management Fig. 4. 
 The overall patient’s neurological status and 
quality of life has improved after subtotal removal and 
radiation therapy. 
 
DISCUSSION 
Diffuse large B cell lymphoma is potentially a fatal 
disease but also potentially a curable illness.
1
 The most 
 
 
Fig. 4: High power view of large size neoplastic cells show-
ing marked pleomorphic nuclei with prominent nuc-
leoli and brisk mitotic activity. (H&E stain, 400 × 
magnification). 
 
 
 
Fig. 5: Immunohistochemical profile. A) Diffuse membra-
nous positivity of Pan B (CD20) stain, B) High Ki-
67 (Mib-1) index, evident as strong nuclear staining 
and C) GFAP stain highlighting scattered glial 
cells. 
 
important step in the treatment of the patient is proper 
excision biopsy reviewed by an expert pathologist. 
The literature review suggested that different chemo-
therapy regimens have been used with up to mark 
results. But there is always a room for radiotherapy for 
bulky lesions which are measuring about 5 to 10 cm. 
 Diffuse large B-cell lymphoma presenting as a 
brain tumor, with or without meningeal or ocular 
involvement, is being seen increasingly in HIV - 
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Fig. 6:  Post surgical PET / CT Scan. 
 
negative patients. Therapy with CHOP-R or with pri-
mary radiotherapy has a poor outcome, with a median 
survival of less than 1 year. It is now clear that treat-
ment regimens that include high - dose methotrexate 
plus or minus high - dose cytarabine plus or minus 
consolidative radiotherapy can achieve long-term, 
disease - free survival in 30% to 50% of patients, with 
the best results in younger patients.
6
 Our team tries to 
avoid radiotherapy in the primary treatment regimen to 
reduce the risk of the development of dementia in 
long-term survivors. This is a particularly serious pro-
blem in patients who are treated after 60 years of age. 
However, in patients in whom primary chemotherapy 
regimens fail, radiotherapy provides an important pal-
liative option.
7
 
 While in comparison studies revealed controversy 
regarding the place of radiotherapy in the management 
of patients with diffuse large B-cell lymphoma who 
have sites of bulky disease at presentation. The defi-
nition of bulky disease has varied from 5 to 10 cm in 
different reports. Some physicians believe that a pat-
ient, who achieves a complete remission with a rituxi-
mab - containing regimen, particularly if defined by 
negative results on a positron emission tomographic 
(PET) scan, does not require consolidative radiothe-
rapy to sites of bulky disease. However, a recent report 
from MD Anderson Cancer Center found that radio-
therapy after CHOP-R chemotherapy improved 5 - 
year progression - free survival (90% vs. 75%) and 
overall survival (91% vs. 83%) in patients with all sta-
ges of disease.
8
 
 Patients received radiotherapy to sites of initially 
bulky disease after the completion of chemotherapy. 
Radiotherapy seemed to eliminate the anticipated neg-
ative prognostic impact of bulky disease.
9
 
 I still offer radiotherapy to most patients with sites 
of bulky disease (i.e., ≥ 10 cm) regardless of the initial 
stage of disease. An equivocal PET scan result at the 
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completion of treatment would make me more likely 
to administer the radiotherapy.
10
 
 Diffuse large B-cell lymphoma is one of the most 
consistently PET – avid lymphomas.11 The standard 
uptake value (SUV) is typically high, with most lym-
phomas having an SUVmax greater than 10 and many 
having an SUVmax greater than 20. PET scans improve 
the accuracy of staging, with as many as 20% to 40% 
of patients having their stage altered after the perfor-
mance of a PET scan.
12-15
 Perhaps the most important 
contribution of PET scans to current management of 
patients with diffuse large B – cell lymphoma is in 
documenting complete remission. It has become clear 
that PET scans are more accurate than CT scans in 
proving complete remission and that a negative PET 
scan result has the greatest impact in predicting pro-
gression – free and overall survival.16-20 In fact, current 
restaging guidelines specify that a negative PET scan 
result is a key factor in documenting complete remis-
sion — something that is particularly useful in patients 
who have a residual mass on CT scan.
21
 
 While reviewing the literature it has been confir-
med that the biopsy for such patients is mandatory and 
detrimental moreover approach regarding providing 
the chemotherapy or radiotherapy can be adjustable. In 
addition due importance is being given to PET / CT 
scanning for definitive treatment and follow up. As in 
our case report radiotherapy was initially instituted 
with future plan of chemotherapy infusions with or 
without methotraxate depending upon the involvement 
of craniospinal axis. 
 There is a documented role of bone marrow trans-
plant in specific cases, this report has limitations to 
further elaborate about the details regarding bone mar-
row biopsy and transplant as our patient had a atypical 
presentation of isolated intra parenchymal lesion with-
out evidence of extra cranial extension.  In comparison 
to do the near total or total excision, subtotal resection 
was contemplated just to avoid unnecessary entry in 
the ventricular system, which could have further dete-
riorated the clinical neurology of an already compro-
mised young patient with severe midline shift on ima-
ging. It has been well seen in the practice and docu-
mented in the literature that while performing the 
transcortical approaches undue access inside the ven-
tricular system may lead to ventriculitis and meningitis 
which can result in increasing the morbidity and mor-
tality of patients. 
 
CONCLUSION 
It has become clear that it is a rare entity we come 
across high grade diffuse large B-cell lymphoma as 
primary central nervous system involvement. There 
are different clinicopathologic syndromes that should 
not all have identical treatment. The unique part of the 
case is the clinical presentation and preoperative dece-
ption of high grade glioma which was proved later 
histo-pathologically a wrong perception. The interest-
ing part of this case was prompt and safe subtotal rese-
ction in terms of decreasing the morbidity and impart-
ing the focused primary central nervous system lym-
phoma treatment protocols considering multidiscip-
linary approach management by neurosurgery, histo-
pathology and oncology disciplines. 
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